NEWS & MEDIA
We’re not only at the front lines of therapeutic advancement, we’re also continuously making headlines in healthcare, business, and research markets.
PRESS RELEASES
BeyondSpring Initiates New Drug Application Rolling Submission for Plinabulin in China for Chemotherapy-Induced Neutropenia
BeyondSpring Initiates New Drug Application Rolling Submission for Plinabulin in China for Chemotherapy-Induced Neutropenia March 30, 2020 Potential to be First Superior Therapy to Standard of Care for Chemotherapy-Induced Neutropenia in 30 Years - - Targeting CIN...
BeyondSpring’s Plinabulin May Prevent Tissue Iron Overload in Anemic Cancer Patients Receiving Chronic Blood Transfusions During Chemotherapy
BeyondSpring's Plinabulin May Prevent Tissue Iron Overload in Anemic Cancer Patients Receiving Chronic Blood Transfusions During Chemotherapy March 23, 2020 New Data to be Presented at NCCN 2020 Annual Conference NEW YORK, March 23, 2020 (GLOBE NEWSWIRE)...
BeyondSpring Files for Patent Protection on BPI-002 for the Treatment of Viral Infections Including COVID-19
BeyondSpring Files for Patent Protection on BPI-002 for the Treatment of Viral Infections Including COVID-19 March 11, 2020 NEW YORK, March 11, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical...
BeyondSpring’s Plinabulin Stimulates Both the Adaptive and Innate Immune System in Cancer Patients
BeyondSpring's Plinabulin Stimulates Both the Adaptive and Innate Immune System in Cancer Patients February 10, 2020 Presentation at the 2020 ASCO-SITC Provides Strong Validation for Plinabulin as a Potent activator of the Innate Immune System NEW YORK, Feb. 10, 2020...
BeyondSpring Appoints Pharma Veterans Drs. Daniel Zabrowski and Ramon Mohanlal to Company’s Board of Directors
BeyondSpring Appoints Pharma Veterans Drs. Daniel Zabrowski and Ramon Mohanlal to Company's Board of Directors January 23, 2020 NEW YORK, Jan. 23, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical...
MEDIA
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.